CALC is trading at $0.74 (down 9.1%) as investors weigh the impact of a $49 million private placement that has triggered significant dilution concerns.

  • While the capital raise extends CalciMedica’s cash runway, it highlights underlying financial vulnerabilities including negative equity and limited revenue.
  • The downward move follows a sharp price jump last week, with sentiment remaining cautious despite strength in the broader market.